eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2014
vol. 10
 
Share:
Share:

Short communication
Chronic total occlusion successfully treated with a bioresorbable everolimus-eluting vascular scaffold

Juan Carlos Rama-Merchan
,
Alessio Mattesini
,
Gianni Dall’Ara
,
Carlo Di Mario

Postep Kardiol Inter 2014; 10, 2 (36): 128–129
Online publish date: 2014/06/26
Article file
- Chronic total.pdf  [0.13 MB]
Get citation
 
 
Fully bioresorbable vascular scaffolds (BVS) are a new approach to the percutaneous treatment of coronary artery disease. These scaffolds provide transient vessel support and drug delivery to the vessel wall without the potential long-term limitations of a traditional metallic drug-eluting stent (DES). The BVS have been shown to restore vascular function and enable positive vascular remodelling; they also do not preclude coronary artery bypass grafting [1–3]. However, BVS have not yet been fully tested in complex lesions, including chronic total occlusion (CTO).
We report a CTO case successfully treated with a second-generation bioabsorbable drug-eluting scaffold.
A 52-year-old woman with type 1 diabetes was admitted to our centre due to severe chronic stable angina. A myocardial perfusion test revealed significant ischaemia involving the anterior wall. The patient underwent coronary angiography which demonstrated total occlusion of the mid-portion of the left anterior descending (LAD) coronary artery (Figure 1 A). Percutaneous coronary intervention (PCI) was performed using a conventional antegrade approach and an everolimus 2.5 mm × 28 mm BVS 1.1 (Absorb BVS, Abbott Vascular, Santa Clara, CA, USA) was implanted in the LAD (Figure 1 B). The scaffold was post-dilated with a 2.5-mm non-compliant balloon, slowly inflated at 12 ATM.
The final angiogram showed satisfactory results with TIMI 3 flow in the LAD (Figure 1 C). Frequency domain optical coherence tomography (FD-OCT) pullback was performed on the implanted scaffold (C7 System, St Jude Medical, St Paul, USA). Longitudinal view and cross-sections demonstrated good strut apposition and scaffold expansion (Figure 2). At the 6-month follow-up the patient remained asymptomatic.

References

1. Ormiston JA, Serruys PW, Regar E. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371: 899-907.
2. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012; 33: 16-25.
3. Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 2011; 123: 779-97.
Copyright: © 2014 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.